Sharon Mates - 06 Mar 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: Chairman, President & CEO, Director
Signature: /s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol: ITCI
Transactions as of: 06 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 08 Mar 2024, 17:59:02 UTC
Previous filing: 05 Mar 2024
Next filing: 11 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Options Exercise		+40,712	+3.9%		1,091,021	06 Mar 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITCI	Restricted Stock Units	Options Exercise	$0	-40,712	-33%	$0.000000	81,425	06 Mar 2024	Common Stock	40,712		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.